Jeffery Kelly, PhD, professor in the Department of Chemistry, has been named to the 2019 class of inductees into the Medicinal Chemistry Hall of Fame. In May of this year, tafamidis, a drug developed in Kelly’s laboratory, was approved by the FDA for the treatment of cardiomyopathy caused by mutant or wild-type transthyretin aggregation in adults. The two formulations of the drug, Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are the first FDA-approved treatments for transthyretin amyloid cardiomyopathy. An induction ceremony and reception were held at the American Chemical Society’s Fall National Meeting in San Diego.